Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

NASH Updates: Intercept Moves Toward Re-Filing, Madrigal De-Risks Phase III

Liver disease — Intercept, Madrigal, Akero, 89Bio update their progress at AASLD

Related Content

Madrigal Solidifies Presumed NASH Lead With 52-Week Data

Jun 25 2021

Akero Sees Across-The-Board NASH Benefit With Efruxifermin, But Faces Competition

Jun 30 2021

89bio Hopes Akero’s Success In Cirrhotic NASH Is Positive For FGF21 Class

Mar 24 2021

89Bio’s NASH Hopes Hang On Demonstrating Best-In-Class FGF21 Profile

Feb 11 2020

Intercept Unlikely To Refile OCA For NASH Before Late 2021

Nov 09 2020

Related Companies

Intercept Pharmaceuticals, Inc.

Akero Therapeutics, Inc.

89bio, Inc.

Bristol Myers Squibb Company

Additional Topics

Clinical Trials Drug Approval Standards Business Strategies Research & Development Liver & Hepatic BioPharmaceutical

More from Clinical Trials

More from R&D

About Us

Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us

Customer Service
SubscribeOpens in new window
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window